Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01948258
Other study ID # 0481
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2013
Est. completion date November 2013

Study information

Verified date January 2018
Source SPD Development Company Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the use of the new Clearblue Advanced Fertility Monitor for one menstrual cycle in a home setting by female volunteers seeking to get pregnant.


Description:

The Clearblue Fertility Monitor is a personal monitor designed to be used with disposable test sticks for the semi-quantitative measurement of estrone-3-glucuronide (E3G) and luteinising hormone (LH) in women's urine. This personal information allows women to identify their fertile window and appropriately time intercourse in order to maximise their chances of conception. A new version of this monitor (Clearblue Advanced Fertility Monitor) has been developed with additional functionality including the option to test for pregnancy.

This study will assess the volunteer ease of use of the new Clearblue Advanced Fertility Monitor and the understanding and interpretation of the results by the user. This is a single centre clinical study which will be conducted by volunteers at their residence and co-ordinated by the clinical department at SPD Development Company Ltd.

A minimum of 100 female volunteers representing the target consumer will be required to use the new Clearblue Advanced Fertility Monitor at home as per the instructions for use. This will involve them setting up the monitor, using the monitor for one full cycle and then setting up the monitor for their next cycle unless they test for pregnancy and get a pregnant result.

At the end of one full cycle, all volunteers will complete a study questionnaire which includes sections on comprehension of the instructions for use, ease of use and interpretation of test results.


Recruitment information / eligibility

Status Completed
Enrollment 395
Est. completion date November 2013
Est. primary completion date November 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Female

- Aged 18 - 45 years

- Willing to provide written informed consent to participate in the study and comply to the investigational procedures

- Naive to similar marketed products including current Clearblue fertility monitor and Persona

- Two natural cycles immediately prior to entering the study, each lasting between 21 and 42 days

- Seeking to become pregnant

Exclusion Criteria:

- Unwilling to provide written informed consent to participate in the study or comply with study procedures

- Employees of SPD, Proctor & Gamble or Alere

- Have a condition that is known to be contra-indicated in pregnancy

- Usually have menstrual cycles which are shorter than 21 days or longer than 42 days

- Using or have used in their last 2 cycles, hormonal contraceptives including oral, emergency oral, implants, patches, transdermal injections, vaginal ring and progesterone intrauterine systems (IUS)

- Using or have used in the last 2 cycles, infertility medications or hormone replacement therapy containing hCG or LH

- Taking clomiphene citrate or other ovulation induction drugs

- Are using any treatment which may affect the menstrual cycle

- Have recently been pregnant, miscarried or breastfeeding

- Have been diagnosed with polycystic ovarian syndrome (PCOS)

- Are peri- or post-menopausal e.g. experiencing symptoms such as irregular menstrual periods, hot flushes, night sweats, sleep disturbances and mood swings

- Are taking antibiotics containing tetracyclines

- Have impaired liver or kidney function

- Have previously participated in a SPD 'trying to conceive' study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Clearblue Advanced Fertility Monitor
Clearblue Advanced Fertility Monitor used for one menstrual cycle in a home setting

Locations

Country Name City State
United Kingdom SPD Development Company Ltd Bedford Bedfordshire

Sponsors (1)

Lead Sponsor Collaborator
SPD Development Company Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Pregnancy Test Result Pregnancy test results will also be compared with both the performance of a currently marketed pregnancy test when used by a trained technician and quantitative hCG concentration. one month
Primary The Ability of the Volunteer to Use the New Clearblue Advanced Fertility Monitoring a Home Setting Acceptance criteria is that =80% of volunteers will score 3 or less on the Likert scale in a home setting by demonstrating ease of use and comprehension of the instructions for use. one month use
Secondary Correct Identification of Monitor Status To demonstrate correct user identification of fertility status and test days and to determine the performance of the monitor in consumer hands. one month
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed NCT02566005 - A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor N/A